Trajectory of extracellular fluid volume over time and subsequent risks of end-stage kidney disease and mortality in chronic kidney disease: a prospective cohort study.
chronic kidney disease
extracellular fluid volume
joint modelling
sodium
trajectory
volume overload
Journal
Journal of internal medicine
ISSN: 1365-2796
Titre abrégé: J Intern Med
Pays: England
ID NLM: 8904841
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
23
04
2020
revised:
08
06
2020
accepted:
09
06
2020
pubmed:
13
7
2020
medline:
4
9
2021
entrez:
13
7
2020
Statut:
ppublish
Résumé
Extracellular fluid volume (ECF) is independently associated with chronic kidney disease (CKD) progression and mortality in patients with CKD, but the prognostic value of the trajectory of ECF over time beyond that of baseline value is unknown. To characterize ECF trajectory and evaluate its association with the risks of end-stage kidney disease (ESKD) and mortality. From the prospective tricentric NephroTest cohort, we included 1588 patients with baseline measured glomerular filtration rate (mGFR) ≥15 mL min Patients were mean age 58.7 years, 66.7% men, mean mGFR of 43.6 ± 18.6 mL min The current value of ECF was associated with the risks of ESKD and mortality, independent of multiple potential confounders, including kidney function decline. This highlights the need for a close monitoring and adjustment of treatment to avoid fluid overload in CKD patients.
Sections du résumé
BACKGROUND
Extracellular fluid volume (ECF) is independently associated with chronic kidney disease (CKD) progression and mortality in patients with CKD, but the prognostic value of the trajectory of ECF over time beyond that of baseline value is unknown.
OBJECTIVES
To characterize ECF trajectory and evaluate its association with the risks of end-stage kidney disease (ESKD) and mortality.
METHODS
From the prospective tricentric NephroTest cohort, we included 1588 patients with baseline measured glomerular filtration rate (mGFR) ≥15 mL min
RESULTS
Patients were mean age 58.7 years, 66.7% men, mean mGFR of 43.6 ± 18.6 mL min
CONCLUSIONS
The current value of ECF was associated with the risks of ESKD and mortality, independent of multiple potential confounders, including kidney function decline. This highlights the need for a close monitoring and adjustment of treatment to avoid fluid overload in CKD patients.
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
193-205Informations de copyright
© 2020 The Association for the Publication of the Journal of Internal Medicine.
Références
Faucon A-L, Flamant M, Metzger M et al. Extracellular fluid volume is associated with incident end-stage kidney disease and mortality in patients with chronic kidney disease. Kidney Int 2019; 96: 1020-9.
Tsai Y-C, Tsai J-C, Chen S-C et al. Association of fluid overload with kidney disease progression in advanced CKD: a prospective cohort study. Am J Kidney Dis 2014; 63: 68-75.
Tai R, Ohashi Y, Mizuiri S, Aikawa A, Sakai K. Association between ratio of measured extracellular volume to expected body fluid volume and renal outcomes in patients with chronic kidney disease: a retrospective single-center cohort study. BMC Nephrol 2014; 15: 189.
Tsai Y-C, Chiu Y-W, Tsai J-C et al. Association of fluid overload with cardiovascular morbidity and all-cause mortality in stages 4 and 5 CKD. Clin J Am Soc Nephrol 2015; 10: 39-46.
Hung S-C, Lai Y-S, Kuo K-L, Tarng D-C. Volume overload and adverse outcomes in chronic kidney disease: clinical observational and animal studies. J Am Heart Assoc 2015; 4: e001918.
McMahon EJ, Bauer JD, Hawley CM et al. A randomized trial of dietary sodium restriction in CKD. J Am Soc Nephrol 2013; 24: 2096-103.
Saran R, Padilla RL, Gillespie BW et al. A randomized crossover trial of dietary sodium restriction in stage 3-4 CKD. Clin J Am Soc Nephrol 2017; 12: 399-407.
Vasavada N, Agarwal R. Role of excess volume in the pathophysiology of hypertension in chronic kidney disease. Kidney Int 2003; 64: 1772-9.
Esmeray K, Dizdar OS, Erdem S, Gunal Aİ. Effect of strict volume control on renal progression and mortality in non-dialysis-dependent chronic kidney disease patients: a prospective interventional study. Med Princ Pract 2018; 27: 420-7.
Zamboli P, De Nicola L, Minutolo R et al. Effect of furosemide on left ventricular mass in non-dialysis chronic kidney disease patients: a randomized controlled trial. Nephrol Dial Transplant 2011; 26: 1575-83.
De Nicola L, Minutolo R, Bellizzi V et al. Achievement of target blood pressure levels in chronic kidney disease: a salty question? Am J Kidney Dis 2004; 43: 782-95.
Moranne O, Froissart M, Rossert J et al. Timing of onset of CKD-related metabolic complications. J Am Soc Nephrol 2009; 20: 164-71.
Flamant M, Vidal-Petiot E, Metzger M et al. Performance of GFR estimating equations in African Europeans: basis for a lower race-ethnicity factor than in African Americans. Am J Kidney Dis 2013; 62: 182-4.
Noordzij M, Leffondré K, van Stralen KJ, Zoccali C, Dekker FW, Jager KJ. When do we need competing risks methods for survival analysis in nephrology? Nephrol Dial Transplant 2013; 28: 2670-7.
Wulfsohn MS, Tsiatis AA. A joint model for survival and longitudinal data measured with error. Biometrics 1997; 53: 330-9.
Fisher LD, Lin DY. Time-dependent covariates in the Cox proportional-hazards regression model. Annu Rev Public Health 1999; 20: 145-57.
Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604.
Rizopoulos D. JM: An R package for the joint modelling of longitudinal and time-to-event data. J Stat Softw 2010; 35: 1-33. https://doi.org/10.18637/jss.v035.i09
Bansal N, Zelnick LR, Himmelfarb J, Chertow GM. Bioelectrical impedance analysis measures and clinical outcomes in CKD. Am J Kidney Dis 2018; 72: 662-72.
Brankovic M, Kardys I, Hoorn EJ, Baart S, Boersma E, Rizopoulos D. Personalized dynamic risk assessment in nephrology is a next step in prognostic research. Kidney Int 2018; 94: 214-7.
Proust-Lima C, Séne M, Taylor JMG, Jacqmin-Gadda H. Joint latent class models for longitudinal and time-to-event data: a review. Stat Methods Med Res 2014; 23: 74-90.
Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl 2012;2: 337-414. https://doi.org/10.1038/kisup.2012.46
Kovesdy CP, Lu JL, Molnar MZ et al. Observational modeling of strict vs conventional blood pressure control in patients with chronic kidney disease. JAMA Intern Med 2014; 174: 1442-9.
Anderson AH, Yang W, Townsend RR et al. Time-updated systolic blood pressure and the progression of chronic kidney disease: a cohort study. Ann Intern Med 2015; 162: 258-65.
Sood MM, Akbari A, Manuel D et al. Time-Varying Association of Individual BP Components with eGFR in Late-Stage CKD. Clin J Am Soc Nephrol 2017; 12: 904-11.
Schrier RW, Fassett RG. A critique of the overfill hypothesis of sodium and water retention in the nephrotic syndrome. Kidney Int 1998; 53: 1111-7.
Schork A, Woern M, Kalbacher H et al. Association of plasminuria with overhydration in patients with CKD. Clin J Am Soc Nephrol 2016; 11: 761-9.
Schrier RW, Gurevich AK, Cadnapaphornchai MA. Pathogenesis and management of sodium and water retention in cardiac failure and cirrhosis. Semin Nephrol 2001; 21: 157-72.
He J, Mills KT, Appel LJ et al. Urinary sodium and potassium excretion and CKD progression. J Am Soc Nephrol 2016; 27: 1202-12.
Firth JD, Raine AE, Ledingham JG. Raised venous pressure: a direct cause of renal sodium retention in oedema? Lancet 1988; 1: 1033-5.
Safar ME, London GM, Plante GE. Arterial stiffness and kidney function. Hypertension 2004; 43: 163-8.
Hung S-C, Kuo K-L, Peng C-H et al. Volume overload correlates with cardiovascular risk factors in patients with chronic kidney disease. Kidney Int 2014; 85: 703-9.
Essig M, Escoubet B, de Zuttere D et al. Cardiovascular remodelling and extracellular fluid excess in early stages of chronic kidney disease. Nephrol Dial Transplant 2008; 23: 239-48.
Briet M, Collin C, Karras A et al. Arterial remodeling associates with CKD progression. J Am Soc Nephrol 2011; 22: 967-74.
Brater DC. Diuretic therapy. N Engl J Med 1998; 339: 387-95.
De Nicola L, Minutolo R, Chiodini P et al. Global approach to cardiovascular risk in chronic kidney disease: reality and opportunities for intervention. Kidney Int 2006; 69: 538-45.
Fan L, Tighiouart H, Levey AS, Beck GJ, Sarnak MJ. Urinary sodium excretion and kidney failure in nondiabetic chronic kidney disease. Kidney Int 2014; 86: 582-8.
Ruggenenti P, Perna A, Loriga G et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet 2005; 365: 939-46.
Alencar de Pinho N, Levin A, Fukagawa M et al. Considerable international variation exists in blood pressure control and antihypertensive prescription patterns in chronic kidney disease. Kidney Int 2019; 96: 983-94.
Ellison DH. Clinical pharmacology in diuretic use. Clin J Am Soc Nephrol 2019; 14: 1248-57.
Faucon A-L. Diuretics and chronic renal failure. Rev Prat 2017; 67: 242-9.
Dal Canton A, Fuiano G, Conte G et al. Mechanism of increased plasma urea after diuretic therapy in uraemic patients. Clin Sci 1985; 68: 255-61.
Vogt L, Waanders F, Boomsma F, de Zeeuw D, Navis G. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol 2008; 19: 999-1007.
Rahman M, Ford CE, Cutler JA et al. Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR. Clin J Am Soc Nephrol 2012; 7: 989-1002.
Kotchen TA, Cowley AW, Frohlich ED. Salt in health and disease - a delicate balance. N Engl J Med 2013; 368: 1229-37.
van Zuilen AD, Bots ML, Dulger A et al. Multifactorial intervention with nurse practitioners does not change cardiovascular outcomes in patients with chronic kidney disease. Kidney Int 2012; 82: 710-7.
Kutlugün AA, Arıcı M, Yıldırım T et al. Daily sodium intake in chronic kidney disease patients during nephrology clinic follow-up: an observational study with 24-hour urine sodium measurement. Nephron Clin Pract 2011; 118: c361-366.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2012; 3: 1-150.
World Health Organization. Salt reduction. https://www.who.int/news-room/fact-sheets/detail/salt-reduction. 2020.
Koomans HA, Roos JC, Boer P, Geyskes GG, Mees EJ. Salt sensitivity of blood pressure in chronic renal failure. Evidence for renal control of body fluid distribution in man. Hypertension 1982; 4: 190-7.
Koomans HA, Roos JC, Dorhout Mees EJ, Delawi IM. Sodium balance in renal failure. A comparison of patients with normal subjects under extremes of sodium intake. Hypertension 1985; 7: 714-21.
Mills KT, Chen J, Yang W et al. Sodium excretion and the risk of cardiovascular disease in patients with chronic kidney disease. JAMA 2016; 315: 2200-10.
Hwang JH, Chin HJ, Kim S et al. Effects of intensive low-salt diet education on albuminuria among nondiabetic patients with hypertension treated with olmesartan: a single-blinded randomized, controlled trial. Clin J Am Soc Nephrol 2014; 9: 2059-69.
Garofalo C, Borrelli S, Provenzano M et al. Dietary salt restriction in chronic kidney disease: a meta-analysis of randomized clinical trials. Nutrients 2018; 10: 732.
Aburto NJ, Ziolkovska A, Hooper L, Elliott P, Cappuccio FP, Meerpohl JJ. Effect of lower sodium intake on health: systematic review and meta-analyses. BMJ 2013; 346: f1326.
Meuleman Y, Hoekstra T, Dekker FW et al. Sodium restriction in patients with CKD: a randomized controlled trial of self-management support. Am J Kidney Dis 2017; 69: 576-86.